Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102345 · ClinicalTrials.gov registry record · Early Phase 1
Lavender vs Zolpidem Sleep Quality During Diagnostic PSG
A Early Phase 1 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 58
- Enrollment target
NCT04102345: Completed Early Phase 1 study, sponsored by HealthPartners Institute.
NCT04102345 is a Early Phase 1 study that has completed, run by HealthPartners Institute. The registered enrollment target is 58 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04102345, a Early Phase 1 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
In this pragmatic, clinical study the investigators propose that lavender aromatherapy is comparable to Zolpidem (Ambien) in improving the quality of diagnostic sleep studies.
Primary Outcome
Percentage of total time in bed actually spent in sleep. It is calculated as sum of Stage N1, Stage N2, Stage N3, and REM sleep, divided by the total time in bed and multiplied by 100. A higher percentage is indicative of more efficient sleep.
Interventions
- OTHER Lavender Aromatherapy
- DRUG Zolpidem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2020-11-10 |
| Phase | Early Phase 1 |
What the finished NCT04102345 record still lists
NCT04102345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Lavender Aromatherapy is the first listed.
NCT04102345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04102345 about?
NCT04102345 is a clinical study titled "Lavender vs Zolpidem Sleep Quality During Diagnostic PSG". In this pragmatic, clinical study the investigators propose that lavender aromatherapy is comparable to Zolpidem (Ambien) in improving the quality of diagnostic sleep studies.
What is the current status of trial NCT04102345?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 58 participants. The study started on 2019-09-04. Estimated completion is 2020-11-10.
What interventions are being tested in trial NCT04102345?
The interventions under investigation include: Lavender Aromatherapy (OTHER), Zolpidem (DRUG).
Who is sponsoring clinical trial NCT04102345?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04102345's enrollment target sits among peer trials
58 441st of 2000 higher than 1,556 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI